Application of machine learning algorithms to predict heat-sensitive angina (HSA) attacks: a multicentric observational cohort study.

Despite major advances in the field of inflammatory bowel diseases (IBD), important unmet needs remain: diagnostic delays, refractory inflammation, treatment intolerance, complications, recurrent hospitalizations and surgery, impaired quality of life, long-term disability, and disparities. The rising global incidence and prevalence of IBD—particularly in newly industrialized regions—adds urgency to defining scalable, evidence-based models for care and harmonized methodologies for research. Addressing these challenges requires sustained international collaboration that can integrate evidence-based medicine, epidemiology, trial methodology, translational science, patient-reported outcomes, definition of new endpoints as well as disease monitoring strategies. IOIBD was conceived as a focused forum designed to resolve foundational problems in disease assessment, trial design, and clinical management. Its model—selective membership, year-round scientific clusters, and consensus-driven outputs—has enabled IOIBD to align the field around practical targets and standardized approaches, while remaining responsive to emerging scientific and societal realities. IOIBD occupies a distinct niche within the global gastroenterology landscape. Unlike large open-membership societies such as the European Crohn’s and Colitis Organisation, the United European Gastroenterology, or the American Gastroenterological Association or the American College of Gastroenterology—which serve broad clinical communities through guidelines, educational meetings, and advocacy—IOIBD functions as a compact, invitation-only global think tank. Its membership is currently capped, including experts spanning multiple disciplines and more than 25 countries, and is intentionally designed to foster accountability, sustained engagement, and rapid consensus. Rather than hosting large-scale open conferences or producing comprehensive clinical practice guidelines, IOIBD focuses on foundational infrastructure: it defines the research agenda, standardizes trial endpoints, and develops the conceptual and methodological frameworks that inform and underpin the work of broader organizations and regulatory agencies—all through considerations that are global in scope. This Agile model enables IOIBD to move efficiently from scientific question to actionable consensus, making it uniquely positioned to interface with regulatory bodies, industry partners, and the wider gastroenterology community as an authoritative and independent source of direction in IBD research and care.